157 related articles for article (PubMed ID: 17114958)
1. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.
Stempak D; Gammon J; Halton J; Moghrabi A; Koren G; Baruchel S
J Pediatr Hematol Oncol; 2006 Nov; 28(11):720-8. PubMed ID: 17114958
[TBL] [Abstract][Full Text] [Related]
2. Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.
Twardowski PW; Smith-Powell L; Carroll M; VanBalgooy J; Ruel C; Frankel P; Synold TW
Cancer Invest; 2008 Feb; 26(1):53-9. PubMed ID: 18181046
[TBL] [Abstract][Full Text] [Related]
3. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.
Young SD; Whissell M; Noble JC; Cano PO; Lopez PG; Germond CJ
Clin Cancer Res; 2006 May; 12(10):3092-8. PubMed ID: 16707607
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.
Morgenstern DA; Marzouki M; Bartels U; Irwin MS; Sholler GL; Gammon J; Yankanah R; Wu B; Samson Y; Baruchel S
Pediatr Blood Cancer; 2014 Jan; 61(1):128-33. PubMed ID: 23956145
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of a pediatric metronomic 4-drug regimen.
André N; Abed S; Orbach D; Alla CA; Padovani L; Pasquier E; Gentet JC; Verschuur A
Oncotarget; 2011 Dec; 2(12):960-5. PubMed ID: 22156656
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
[TBL] [Abstract][Full Text] [Related]
10. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
Casanova M; Ferrari A; Bisogno G; Merks JH; De Salvo GL; Meazza C; Tettoni K; Provenzi M; Mazzarino I; Carli M
Cancer; 2004 Oct; 101(7):1664-71. PubMed ID: 15378498
[TBL] [Abstract][Full Text] [Related]
11. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.
Sterba J; Valik D; Mudry P; Kepak T; Pavelka Z; Bajciova V; Zitterbart K; Kadlecova V; Mazanek P
Onkologie; 2006 Jul; 29(7):308-13. PubMed ID: 16874014
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Robison NJ; Campigotto F; Chi SN; Manley PE; Turner CD; Zimmerman MA; Chordas CA; Werger AM; Allen JC; Goldman S; Rubin JB; Isakoff MS; Pan WJ; Khatib ZA; Comito MA; Bendel AE; Pietrantonio JB; Kondrat L; Hubbs SM; Neuberg DS; Kieran MW
Pediatr Blood Cancer; 2014 Apr; 61(4):636-42. PubMed ID: 24123865
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.
Felgenhauer JL; Nieder ML; Krailo MD; Bernstein ML; Henry DW; Malkin D; Baruchel S; Chuba PJ; Sailer SL; Brown K; Ranganathan S; Marina N
Pediatr Blood Cancer; 2013 Mar; 60(3):409-14. PubMed ID: 23065953
[TBL] [Abstract][Full Text] [Related]
14. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer.
Kieran MW; Turner CD; Rubin JB; Chi SN; Zimmerman MA; Chordas C; Klement G; Laforme A; Gordon A; Thomas A; Neuberg D; Browder T; Folkman J
J Pediatr Hematol Oncol; 2005 Nov; 27(11):573-81. PubMed ID: 16282886
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma.
Krzyzanowska MK; Tannock IF; Lockwood G; Knox J; Moore M; Bjarnason GA
Cancer Chemother Pharmacol; 2007 Jun; 60(1):135-41. PubMed ID: 17009033
[TBL] [Abstract][Full Text] [Related]
16. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.
Fousseyni T; Diawara M; Pasquier E; André N
J Pediatr Hematol Oncol; 2011 Jan; 33(1):31-4. PubMed ID: 21164360
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.
Aquino VM; Weitman SD; Winick NJ; Blaney S; Furman WL; Kepner JL; Bonate P; Krailo M; Qu W; Bernstein M
J Clin Oncol; 2004 Apr; 22(8):1413-9. PubMed ID: 15084615
[TBL] [Abstract][Full Text] [Related]
18. Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study.
André N; Rome A; Coze C; Padovani L; Pasquier E; Camoin L; Gentet JC
Clin Ther; 2008 Jul; 30(7):1336-40. PubMed ID: 18691994
[TBL] [Abstract][Full Text] [Related]
19. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
Shaked Y; Emmenegger U; Francia G; Chen L; Lee CR; Man S; Paraghamian A; Ben-David Y; Kerbel RS
Cancer Res; 2005 Aug; 65(16):7045-51. PubMed ID: 16103050
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
